Niclosamide - TFF Pharmaceuticals
Latest Information Update: 02 Jun 2025
At a glance
- Originator TFF Pharmaceuticals
- Class Anthelmintics; Anti-inflammatories; Antibacterials; Antineoplastics; Antivirals; Benzamides; Chlorophenols; Nitrobenzenes; Skin disorder therapies; Small molecules
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers; MTOR protein inhibitors; Notch signalling pathway inhibitors; STAT3 transcription factor inhibitors; Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 03 Mar 2025 Discontinued - Phase-I for COVID-2019 infections (In volunteers, In adults) in Canada (Inhalation)
- 03 Mar 2025 Discontinued - Preclinical for COVID-2019 infections in USA (PO)
- 28 Dec 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers, In adults) in Canada (Inhalation, Powder)